1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma : a case report
- Contribution to journal › Article
-
Mark
Seizure-Related Homolog Protein 6 (SEZ6) : Biology and Therapeutic Target in Neuroendocrine Carcinomas
- Contribution to journal › Scientific review
- 2024
-
Mark
Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted
- Contribution to journal › Article
- 2023
-
Mark
Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer : A Sub-Study of RASTEN—A Randomized Trial with Low Molecular Weight Heparin
- Contribution to journal › Article
- 2022
-
Mark
Coagulation and other aspects of the cardiovascular system in small cell lung cancer
(2022) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)
- Contribution to journal › Article
- 2019
-
Mark
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)
- Contribution to journal › Article
-
Mark
Biomarkers of venous thromboembolism in cancer : A silent echo from local events?
- Contribution to journal › Debate/Note/Editorial
- 2018
-
Mark
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer : The RASTEN trial
- Contribution to journal › Article
-
Mark
Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer : A sub-study of RASTEN - A randomized trial with low molecular weight heparin
- Contribution to journal › Article
